The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats

European Journal of Pharmacology

Volumn 693, Issue 1-3, 2012, Pages 51-56

  Prins, Jolanda ^a   Kenny, Paul J ^b   Doomernik, Ivo ^a   Schreiber, Rudy ^c   Olivier, Berend ^a,d   Mechiel Korte, S ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anhedonia; Dopamine; DOV 21,947; DOV 216,303; EB 1010; Major depression; Monoamines; Reward; TRI; Triple reuptake inhibitor

Indexed keywords

AMITIFADINE; AMPHETAMINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ELECTROENCEPHALOGRAM; LATENT PERIOD; MALE; NEUROTRANSMISSION; NONHUMAN; OUTCOME ASSESSMENT; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RAT; REWARD; SELF STIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; RATS; RATS, WISTAR; REWARD; SELF STIMULATION;

EID: 84866300005     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.07.047     Document Type: Article

References (43)

1. B. Beer, J. Stark, P. Krieter, P. Czobor, G. Beer, A. Lippa, and P. Skolnick DOV 216,303, a triple reuptake inhibitor: safety, tolerability, and pharmacokinetic profile J. Clin. Pharmacol. 44 2004 1360 1367 (Pubitemid 39518641)
2. M.E. Breuer, L. Groenink, R.S. Oosting, E. Buerger, M. Korte, B. Ferger, and B. Olivier Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats Eur. J. Pharmacol. 616 2009 134 140
3. B.J. Caldarone, N.E. Paterson, J. Zhou, D. Brunner, A.P. Kozikowski, K.G. Westphal, G.A. Korte-Bouws, J. Prins, S.M. Korte, B. Olivier, and A. Ghavami The novel triple reuptake inhibitor, JZAD-IV-22, exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties J. Pharmacol. Exp. Ther 335 2010 762 770
4. W.A. Carlezon, Jr., and E.H. Chartoff Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation Nat. Protoc. 2 2007 2987 2995
5. K.D. Carr Effects of antibodies to dynorphin A and beta-endorphin on lateral hypothalamic self-stimulation in ad libitum fed and food-deprived rats Brain Res. 534 1990 8 14
6. J.F. Cryan, A.W. Bruijnzeel, K.L. Skjei, and A. Markou Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat Psychopharmacology (Berl) 168 2003 347 358 (Pubitemid 36920920)
7. J.F. Cryan, D. Hoyer, and A. Markou Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents Biol. Psychiatry 54 2003 49 58 (Pubitemid 36776723)
8. S. Dhillon, L.P. Yang, and M.P. Curran Spotlight on bupropion in major depressive disorder CNS Drugs 22 2008 613 617
9. G. Di Chiara, P. Loddo, and G. Tanda Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression Biol. Psychiatry 46 1999 1624 1633 (Pubitemid 30001604)
10. B.W. Dunlop, and C.B. Nemeroff The role of dopamine in the pathophysiology of depression Arch. Gen. Psychiatry 64 2007 327 337 (Pubitemid 46376789)
11. J.F. Goldberg, K.E. Burdick, and C.J. Endick Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression Am. J. Psychiatry 161 2004 564 566 (Pubitemid 38326114)
12. B.P. Guiard, M. El Mansari, and P. Blier Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors Curr. Drug Targets 10 2009 1069 1084
13. S. Gupta, J.L. Vincent, and B. Frank Pramipexole: augmentation in the treatment of depressive symptoms CNS Spectr. 11 2006 172 175
14. S. Kapur, and J.J. Mann Role of the dopaminergic system in depression Biol. Psychiatry 32 1992 1 17
15. P.J. Kenny Brain reward systems and compulsive drug use Trends Pharmacol. Sci. 28 2007 135 141 (Pubitemid 46283593)
16. P.J. Kenny, S.A. Chen, O. Kitamura, A. Markou, and G.F. Koob Conditioned withdrawal drives heroin consumption and decreases reward sensitivity J. Neurosci. 26 2006 5894 5900 (Pubitemid 44318354)
17. P.J. Kenny, and A. Markou Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity Neuropsychopharmacology 31 2006 1203 1211 (Pubitemid 43971837)
18. P.J. Kenny, I. Polis, G.F. Koob, and A. Markou Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats Eur. J. Neurosci. 17 2003 191 195 (Pubitemid 36098891)
19. C. Kornetsky, and R.U. Esposito Euphorigenic drugs: effects on the reward pathways of the brain Fed. Proc. 38 1979 2473 2476 (Pubitemid 10249276)
20. G.S. Kranz, S. Kasper, and R. Lanzenberger Reward and the serotonergic system Neuroscience 166 2010 1023 1035
21. M.J. Kuhar, M.C. Ritz, and J.W. Boja The dopamine hypothesis of the reinforcing properties of cocaine Trends Neurosci. 14 1991 299 302
22. K. Lee, and C. Kornetsky Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation Pharmacol. Biochem. Behav. 60 1998 539 544 (Pubitemid 28282696)
23. N.J. Leith, and R.J. Barrett Amphetamine and the reward system: evidence for tolerance and post-drug depression Psychopharmacologia 46 1976 19 25
24. D. Lin, G.F. Koob, and A. Markou Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat - interactions between the two drugs Psychopharmacology (Berl) 145 1999 283 294 (Pubitemid 29393478)
25. D. Lin, G.F. Koob, and A. Markou Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations Pharmacol. Biochem. Behav. 65 2000 407 417 (Pubitemid 30100671)
26. A. Markou, and G.F. Koob Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations Physiol. Behav. 51 1992 111 119
27. D.M. Marks, C.U. Pae, and A.A. Patkar Triple reuptake inhibitors: a premise and promise Psychiatry Investig. 5 2008 142 147
28. D.M. Marks, C.U. Pae, and A.A. Patkar Triple reuptake inhibitors: the next generation of antidepressants Curr. Neuropharmacol. 6 2008 338 343
29. M.J. Millan Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 2009 53 77
30. C.A. Naranjo, L.K. Tremblay, and U.E. Busto The role of the brain reward system in depression Prog. Neuropsychopharmacol. Biol. Psychiatry 25 2001 781 823 (Pubitemid 32374967)
31. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol. Psychiatry 59 2006 1151 1159 (Pubitemid 44192421)
32. N.E. Paterson, S. Semenova, and A. Markou The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat Psychopharmacology (Berl) 198 2008 351 362
33. L. Pellegrino, A. Pellegrino, and A. Cushman A stereotaxic Atlas of the Rat Brain 1979 Plenum Press New York
34. J. Prins, D.A. Denys, K.G. Westphal, G.A. Korte-Bouws, M.S. Quinton, R. Schreiber, L. Groenink, B. Olivier, and S.M. Korte The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats Eur. J. Pharmacol. 633 2010 55 61
35. J. Prins, K.G. Westphal, G.A. Korte-Bouws, M.S. Quinton, R. Schreiber, B. Olivier, and S.M. Korte The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats Pharmacol. Biochem. Behav. 97 2011 444 452
36. A.C. Sanders, A.J. Hussain, R. Hen, and X. Zhuang Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward Neuropsychopharmacology 32 2007 2321 2329 (Pubitemid 47587680)
37. P. Skolnick, and A.S. Basile Triple reuptake inhibitors (broad spectrum antidepressants) CNS Neurol. Disord. Drug Targets 6 2007 141 149 (Pubitemid 46681774)
38. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa Preclinical and clinical pharmacology of DOV 216,303, a triple reuptake inhibitor CNS Drug Rev. 12 2006 123 134 (Pubitemid 44300380)
39. P. Tran, P. Skolnick, P. Czobor, N.Y. Huang, M. Bradshaw, A. McKinney, and M. Fava Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial J. Psychiatr. Res. 46 2012 64 71
40. L.K. Tremblay, C.A. Naranjo, L. Cardenas, N. Herrmann, and U.E. Busto Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine Arch. Gen. Psychiatry 59 2002 409 416 (Pubitemid 34477674)
41. L.K. Tremblay, C.A. Naranjo, S.J. Graham, N. Herrmann, H.S. Mayberg, S. Hevenor, and U.E. Busto Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe Arch. Gen. Psychiatry 62 2005 1228 1236 (Pubitemid 41586922)
42. M.H. Trivedi, M. Fava, S.R. Wisniewski, M.E. Thase, F. Quitkin, D. Warden, L. Ritz, A.A. Nierenberg, B.D. Lebowitz, M.M. Biggs, J.F. Luther, K. Shores-Wilson, and A.J. Rush Medication augmentation after the failure of SSRIs for depression N. Engl. J. Med. 354 2006 1243 1252
43. P. Willner The mesolimbic dopamine system as a target for rapid antidepressant action Int. Clin. Psychopharmacol. 12 Suppl 3 1997 S7 14